乳腺癌脑转移的信号通路和分子机制的研究进展

doi:10.11904/j.issn.1002-3070.2017.05.016

摘要/Abstract

摘要： 乳腺癌是女性发病率较高的癌症之一,经常发生转移的部位是肺、骨、肝脏和中枢神经系统,其中中枢神经系统转移的发生率大约为15%。目前已知乳腺癌发生脑转移的信号通路可能有Wnt和Notch通路、EGFR和PTEN通路,与乳腺癌脑转移相关的受体可能有VEGF和STAT3、微管蛋白和TOP2A、BNC1、GALNT9、CCDC8、HER2、HER3、MMP、FBPS、肌氨酸等。本文对可能导致乳腺癌脑转移的信号通路和分子机制进行综述,希望为乳腺癌脑转移的靶向治疗提供新的思路。

关键词: 乳腺癌, 脑转移, 机制

Abstract: Breast cancer is one of the highest incidence of cancer in women,most frequent sites of metastasis are the lung,bone,liver,and central nervous system.The incidence of central nervous system metastasis is about 15%.At present,there are Wnt and Notch pathways,EGFR and PTEN pathways,which may be related to the brain metastases in breast cancer.There may be related to VEGF and Stat3,tubulin and TOP2A,BNC1,GALNT9,CCDC8,HER2,HER3,MMP,FBPS,sarcosine and other factors.This paper summarizes the signaling pathways and molecular mechanisms that may lead to brain metastases in breast cancer,and we hope to provide new ideas for targeted therapy of brain metastases in breast cancer.

Key words: Breast cancer, Brain metastases, Mechanisms

中图分类号:

R737.9

靳团综述, 张清媛审校. 乳腺癌脑转移的信号通路和分子机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 468-471.

JIN Tuan, ZHANG Qingyuan. Research propress in signaling pathways and molecular mechanisms of brain metastases in breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 468-471.

参考文献

1 Rippaus N,Taggart D,Williams J,et al.Metastatic site-specific polarization of macrophages in intracranial breast cancer metastases[J].Oncotarget,2016,7(27):41473-41487.
2 Lyle LT,Lockman PR,Adkins CE,et al.Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer[J].Clin Cancer Res,2016,22(21):5287-5299.
3 Medress Z,Hayden GM.Molecular and genetic predictors of breast-to-brain metastasis:review and case presentation[J].Cureus,2015,7(1):e246.
4 Shima H,Yamada A,Ishikawa T,et al.Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?[J].Gland Surg,2017,6(1):82-88.
5 Nam D,Jeon HS,Kim M,et al.Activation of notch signaling in a xenograft model of brain metastasis[J].Clin Cancer Res,2008,14(13):4059-66.
6 Witzel I,Oliveiraferrer L,Pantel K,et al.Breast cancer brain metastases:biology and new clinical perspectives[J].Breast Cancer Res,2016,18(1):1-9.
7 Soffietti R,Ruda R,Trevisan E.Brain metastases:current management and new developments[J].Curr Opin Oncol,2008,20(6):676-684.
8 Takagi S,Banno H,Hayashi A,et al.HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285[J].Oncoscience,2014,1(3):196-204.
9 Momeny M,Saunus JM,Marturana F,et al.Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines[J].Oncotarget,2014,6(6):3932.
10 Altundag K.Tumor types,breast tumor subtypes and extension of systemic disease may influence outcome in cancer patients with brain metastases[J].J Neurooncol,2017[Epub ahead of print].
11 Lee HT,Xue J,Chou PC,et al.Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells[J].Oncotarget,2015,6(12):10016-10029.
12 Langsenlehner U,Hofmann G,Renner W,et al.Association of vascular endothelial growth factor-A gene polymorphisms and haplotypes with breast cancer metastases[J].Acta Oncol,2015,54(3):368-376.
13 Kanojia D,Morshed RA,Zhang L,et al.βⅢ-tubulin regulates breast cancer metastases to the brain[J].Mol Cancer Ther,2015,14(5):1152-1161.
14 Yang Z,Liu Y,Shi C,et al.Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways[J].Oncol Rep,2017,37(2):1011-1019.
15 Pangeni RP,Channathodiyil P,Huen DS,et al.The GALNT9,BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain[J].Clinical Epigenetics,2015,7:57.
16 Hedayatizadeh-Omran A,Rafiei A,Alizadeh-Navaei R,et al.Role of HER2 in brain metastasis of breast cancer:a systematic review and meta-analysis[J].Asian Pac J Cancer Prev,2015,16(4):1431-1434.
17 Wu K,Fukuda K,Xing F,et al.Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer[J].J Biol Chem,2015,290(15):9842-9854.
18 Liu J,Jin X,Liu KJ,et al.Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage[J].J Neurosci,2012,32(9):3044-3057.
19 Khan AP,Rajendiran TM,Bushra A,et al.The role of sarcosine metabolism in prostate cancer progression[J].Neoplasia,2013,15(5):491-501.
20 Lucarelli G,Ditonno P,Bettocchi C,et al.Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer[J].Future Oncol,2013,9(6):899-907.
21 Yoon JK,Kim DH,Koo JS.Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer[J].J Transl Med,2014,12:149.
22 Baum CE,Price DK,Figg WD.Sarcosine as a potential prostate cancer biomarker and therapeutic target[J].Cancer Biol Ther,2010,9(5):341-342.
23 Cha YJ,Kim dH,Jung WH,et al.Expression of sarcosine metabolism-related proteins according to metastatic site in breast cancer[J].Int J Clin Exp Pathol,2014,7(11):7824-7833.
24 Ward PS,Thompson CB.Metabolic reprogramming:a cancer hallmark even warburg did not anticipate[J].Cancer cell,2012,21(3):297-308.
25 Locasale JW,Cantley LC.Metabolic flux and the regulation of mammalian cell growth[J].Cell Metab,2011,14(4):443-451.
26 Chen J,Lee HJ,Wu X,et al.Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain[J].Cancer Res,2015,75(3):554-565.
27 Woolston CM,Deen S,Al-Attar A,et al.Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum-based chemotherapy[J].Free Radic Biol Med,2010,49(8):1263-1272.
28 Yang W,Zou L,Huang C,et al.Redox regulation of cancer metastasis:molecular signaling and therapeutic opportunities[J].Drug Dev Res,2014,75(5):331-341.
29 Kim HM,Jung WH,Koo JS.Expression of reactive oxygen species-related proteins in metastatic breast cancer is dependent on the metastatic site[J].Int J Clin Exp Pathol,2014,7(12):8802-8812.
30 Gorrini C,Harris IS,Mak TW.Modulation of oxidative stress as an anticancer strategy[J].Nat Rev Drug Discov,2013,12(12):931-947.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[8]	常晓霞综述, 宋冰冰, 刘家仁审校. 植物化学物增加肿瘤细胞对化疗药物敏感性的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 67-72.
[9]	阚钧, 周岱翰综述, 张恩欣审校. 肿瘤合并心血管疾病的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 558-561.
[10]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[11]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.
[12]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[13]	范宁宁, 耿敬姝. 长链非编码RNA MEG3在人胶质瘤细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(3): 219-223.
[14]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[15]	张永欣, 黄河. Galectin-9与多种恶性肿瘤的研究进展及作用机制探讨[J]. 实用肿瘤学杂志, 2018, 32(2): 159-163.